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Introduction {#sec001}
============

Cyclosporine A (CsA) is a potent immunosuppressant agent that is widely used in solid organ transplantation. However, CsA use is associated with several unwanted side effect including nephrotoxicity and hypertension \[[@pone.0231472.ref001]\]. The incidence of chronic kidney disease (CKD) due to the use of calcineurin inhibitors (CNIs) such as CsA was reported in a cohort study of non-kidney transplant recipients (mostly liver, heart, and lung) \[[@pone.0231472.ref002]\]. In the mentioned study, CsA was given to 60% of the patients and was followed for 36 months. At the end of the study, 17% of the participants developed CKD (defined as an estimated GFR ≤29 mL/min/1.73 m^2^). The exact mechanism for CsA induced nephrotoxicity remains obscure. However, its immunosuppressive action involves intracellular interaction with calcineurin phosphatase that reduces the production of interleukin-2 (IL-2) which is an inflammatory cytokine. Initially, CsA binds to a specific family of cytoplasmic receptors known as cyclophilins and forms a complex that binds to and inhibits calcineurin, a transcription factor within T-lymphocytes cytoplasm \[[@pone.0231472.ref003], [@pone.0231472.ref004]\]. CsA prevents the de-phosphorylation of calcineurin and blocks the cellular mechanisms required for up-regulation of mRNA expression. These effects of CsA regulate the synthesis of many lymphokine mediators such as IL-2 and interferon-ɤ which is critical for T-lymphocyte proliferation and maturation, and macrophage activation \[[@pone.0231472.ref005]\].

CsA induced nephrotoxicity has been extensively reported in humans \[[@pone.0231472.ref006]--[@pone.0231472.ref008]\]. Patients treated chronically with CsA showed decreased glomerular filtration and renal perfusion accompanied by reduced proximal tubules reabsorptive capacity \[[@pone.0231472.ref006]\]. In another study, there was an increase in renal vascular resistance due to elevated levels of thromboxane in renal allograft recipients treated with CsA \[[@pone.0231472.ref007]\]. On another hand, CsA induced nephrotoxicity in experimental animals was extensively studied. Literature reported on CsA induced nephrotoxicity demonstrated that renal function can be compromised and a reduction of glomerular filtration and creatinine clearance was reported before in rats \[[@pone.0231472.ref009]\]. Moreover, CsA mediated water and sodium retention was shown to contribute to the development of hypertension in this model of renal injury in dogs \[[@pone.0231472.ref010]\]. Activation of renin-angiotensin-aldosterone via the effects of angiotensin II on angiotensin Type 1 (AT~1~) receptors produced renal vasoconstriction and promoted renal tissue fibrosis in rats \[[@pone.0231472.ref005], [@pone.0231472.ref011]\]. The renal vasoconstriction can cause to tissue hypoxia and enhance the formation of reactive oxygen species that ultimately cause cellular injury and apoptosis.

NADPH oxidase (NOX) enzyme catalyzes the transfer of electrons from NADPH to molecular oxygen and generates oxygen free radical (O~2~^-^). It was suggested that NOX4 is the predominant source of O~2~^-^ generation in the renal cortex homogenate \[[@pone.0231472.ref012]\]. Under physiological conditions, O~2~^-^ present at low levels due to the scavenging activity of superoxide dismutase (SOD) enzyme which converts O~2~^-^ into H~2~O~2~. The later itself is a bioactive molecule that can be broken down to H~2~O by intracellular catalase enzyme. Although NOX4 have low levels of constitutive activity normally but in response to cytokines \[[@pone.0231472.ref013]\] and growth factors \[[@pone.0231472.ref014]\], NOX activity can increase significantly. Thus, NOX-generated O~2~^-^ becomes exceedingly greater than endogenous antioxidant defence capacity and this leads to oxidative stress and tissue injury. As reviewed before, NADPH oxidase homologues are differentially expressed in endothelial, smooth muscle and infiltrating immune cells \[[@pone.0231472.ref015]\] indicating a wide range of effects at different levels in these cells.

Human studies reported the effects of NOX4 on vascular tissues such as coronary and peripheral arteries with contribution to atherosclerosis and endothelial dysfunction in these vessels \[[@pone.0231472.ref016], [@pone.0231472.ref017]\]. However, the pattern of and physiological importance of NOX4 expression in human kidney is not fully elucidated. A clinical study depicted the presence of NOX5 in the renal vasculature \[[@pone.0231472.ref018]\], while another study showed correlation between NOX5 expression in the kidney and tissue injury in diabetic nephropathy \[[@pone.0231472.ref019]\]. The aetiology of excessive NOX4 during disease was found to be related at least in part to higher activity of transforming growth factor-beta (TGF-β) in a variety of cell types including endothelial and kidney cells \[[@pone.0231472.ref020], [@pone.0231472.ref021]\]. Similarly, it was also reported that tumor necrosis factor-alpha (TNF-α) enhances the expression of NOX4 in a variety of vascular cells \[[@pone.0231472.ref022]\].

A previous study on rats revealed that apocynin significantly ameliorates inflammatory response and terminates the disease process by inhibiting NOX4. It was suggested that apocynin significantly down regulates NOX expression via activated PI3K/Akt and glycogen synthase kinase-3β (GSK-3β) pathway which is involved in the regulation of cellular inflammation and oxidative stress \[[@pone.0231472.ref023]\]. However, the role of NADPH oxidase in the mechanism of kidney injury and inflammation due to CsA is not fully understood. We hypothesized that in a model of CsA-induced renal injury and inflammation inhibition of NADPH oxidase by apocynin and H~2~O~2~ scavenging by catalase can ameliorate kidney injury and restore renal excretory function. Renal function and haemodynamics, and expression of NOX4 in kidney homogenate were examined in CsA rats following 14 days treatment with apocynin, catalase, and their combination.

Materials and methods {#sec002}
=====================

Animals {#sec003}
-------

The study was performed in accordance with the guidelines of Animal Care and Use Committee in Universiti Sains Malaysia (USM) with the approval letter number USM/IACUC/2017/(106)844. Animal procedures were done under The Malaysian Code for the Care and Use of Animals for Scientific Purposes (MyCode) adapted from the Australian Code for the Care and Use of Animals for Scientific Purposes 8th Edition published by the National Health and Medical Research Council of Australia. Experiments were performed on a total of 64 adult male Wistar-Kyoto rats weighing 200-250g. Animals were procured from the Central Animal Facility of USM, Penang, Malaysia and were housed in the Animal Care Facility at the School of Pharmaceutical Sciences, USM, Penang, under a 12-h light-dark cycle, a temperature of 24°C and a humidity of 60%. Rats were provided with commercial rat 56chow (Gold Coin Sdn. Bhd., Penang, Malaysia) and tap water *ad libitum*. All animals were randomly assigned into two main groups namely, a CsA-induced renal failure group (25 mg/kg/day via gavage, Neoral^®^, Novartis, Basel, Switzerland) and a control group (receiving the same volume of distilled water via gavage). Each of these groups was then sub-divided into four groups (n = 8) based on whether treated or not with apocynin (2.5 mmol/L p.o.), catalase (10000 U/Kg/day i.p.), and a combination of apocynin and catalase (Sigma-Aldrich, St. Louis, Missouri, United States) once daily for 14 days. Study was terminated on day 14 where acute experiments were performed on rats and kidneys were harvested for histopathology.

Metabolic and renal functional studies {#sec004}
--------------------------------------

Weekly metabolic data were collected throughout the study using metabolic cages (Nalgene^®^, Thermo Scientific, Philadelphia, USA) where animals were kept for 24 hours. Body weight, water intake and urine output were recorded. Blood samples (500 μl) were obtained from the tail vein. Blood and urine samples were centrifuged at 3500 rpm for 10 minutes and the supernatants were collected before being stored at -30°C for later biochemical analysis. Plasma and urine creatinine (Jaffe's reaction), and urinary protein levels (Bradford's Assay) were measured spectrophotometrically (PowerWave X340, BioTek Instrument Inc., Vermont, USA) while plasma and urinary sodium and potassium concentrations were measured using a flame photometer (Jenway, PFP-7, England, UK). Creatinine clearance (CrCl), fractional sodium excretion (FE~Na~^+^) and urinary protein excretion were calculated using standard equations as previously reported \[[@pone.0231472.ref009]\]. The BUN in this study was determined by urease/glutamate dehydrogenase method using a biochemical analyser (Biosystem^®^, Shanghai, China). Methodology for measuring BUN was followed as directed by manufacturer.

Systolic blood pressure measurement {#sec005}
-----------------------------------

Weekly non-invasive blood pressure was measured using the CODA^®^ tail cuff plethysmography method (Kent Scientific Corporation, Torrington, CT, USA). Plethysmography utilises blood volume changes in the tail to detect blood pressure. Prior to entering the experimental protocol, the animals were subjected to three-day acclimatization. During each session, a total of 10 consecutive readings were selected from each rat and average values were determined.

Hemodynamic study {#sec006}
-----------------

### General preparation and surgical procedure {#sec007}

General surgical procedures were performed according to established protocols from this laboratory \[[@pone.0231472.ref024]\]. Overnight-fasted rats were anesthetized with an i.p. injection of 60 mg/kg sodium pentobarbitone (Nembutal^®^, CEVA, Santé Animale, Libourne, France). Tracheotomy (PE240, Portex, Kent, UK) was performed through a small incision to facilitate respiration and the left jugular vein was cannulated (PE50, Portex, UK) to enable supplemental anaesthesia administration (15 mg/kg in 0.9%NaCl) as necessary. The right carotid artery was cannulated (PE50) and pushed up to the level of the aortic arch to allow continuous blood pressure recording using a fluid filled pressure transducer (P23 ID Gould, Statham Instrument, London, UK). A midline incision was made in the anterior abdomen to expose the left kidney and iliac artery. A cannula (PE50) was inserted into the iliac artery past the iliac bifurcation into the abdominal aorta to the level of renal artery such that its bevelled tip faced the entrance of the renal artery to enable direct delivery of saline (9g/L NaCl) at a rate of 6 ml/kg/h using a perfusion pump (Perfusor Secura FT 50mL, B. Braun Medical AG, Sempach, Switzerland) throughout the entire study period. A second pressure transducer was attached to the renal arterial cannula and both pressure transducers from the carotid and the renal arteries were attached to a computerized data acquisition system (PowerLab^®^, AD Instruments, Sydney, Australia) for concomitant and continuous blood pressure recordings. A laser Doppler flow probe (OxyFlow, ADInstruments, Sydney, Australia) linked to a blood flowmeter was place on the left kidney capsule for renal cortical blood perfusion (RCBP) measurement.

### Measurement of pulse wave velocity {#sec008}

Pulse wave velocity (PWV) was measured as previously reported \[[@pone.0231472.ref024]\]. PWV is a widely used marker of arterial stiffness and is studied in many pathologies such as left ventricular hypertrophy \[[@pone.0231472.ref025]\], hypertension \[[@pone.0231472.ref026], [@pone.0231472.ref027]\], renal failure \[[@pone.0231472.ref024]\] and diabetes \[[@pone.0231472.ref028]\]. In humans, pulse wave velocity is utilized as a predictor of cardiovascular events and mortality \[[@pone.0231472.ref029]\]. Upon completion of the surgical procedures, a stabilization period of one hour was given to allow equilibrium. Pulse pressure wave was recorded at a sampling rate of 400 Hz for 30 min. At the end of the experiment, animals were euthanized with an overdose (200 mg/kg) of sodium pentobarbitone and full contour of the aorta was exposed. The propagation distance (*d*) between the tips of the two cannulas was measured by locating a damp thread over the contour of the aorta. Whereas, the propagation time (*t*) for the blood pressure wave which moves from the aortic arch to abdominal aorta was measured manually using the time delay between the upstrokes (foot) of each pressure wave front by employing "foot to foot' technique \[[@pone.0231472.ref030]\]. The values of PWV were calculated by dividing *d* by *t* and expressed in units of meters per second. β-index was calculated to evaluate the participation of diastolic blood pressure (DBP) in increasing arterial stiffness. It was calculated using the following formula (β-index = 2.2×(PWV)^2^/DBP) according to a previous report \[[@pone.0231472.ref031]\].

Biochemical analysis for oxidative stress marker {#sec009}
------------------------------------------------

At the end of the acute experimental protocol, a 3 mL arterial blood sample was withdrawn via the carotid artery cannula and centrifuged at 3500 rpm for 10 minutes. The plasma samples were then stored at -30°C for further analysis of oxidative stress markers. Furthermore, kidney tissues were extracted at the end of the acute experiment and processed for oxidative stress biomarkers according to manufacturer's guidelines. The extent of lipid peroxidation was accessed by measuring malondialdehyde (MDA) formation using the thiobarbituric acid reaction method \[[@pone.0231472.ref032]\]. Malondialdehyde reacts with thiobarbituric acid in acidic medium to give a pink-coloured pigment at 95°C. Superoxide dismutase (SOD) activity in the plasma was determined spectrophotometrically using an assay kit via a method established by Oyanagui \[[@pone.0231472.ref033]\]. SOD activities in the samples were determined by hydroxylamine assay developed from xanthine oxidase assay. Briefly, the test principle is as follows: superoxide anions are generated by xanthine and xanthine oxidase system. These superoxide anions oxidize hydroxylamine leading to formation of nitrite. This nitrite reacts with naphthalene diamine and sulfanilic acid to produce a coloured product. Indirect measurement of nitric oxide (NO) activity was done using a method described in a previous study \[[@pone.0231472.ref034]\] which involved a reaction between nitroxides and sulfanilic acid, and N-(1-naphthyl) ethylenediamine that generates a coloured product that can be detected using spectrophotometry. In the present study, the principle test was done according to nitrate reductase method. Since the final stable end product of NO in vivo are NO~2~^-^ and NO~3~^-^. Thus, the total of both NO~2~^-^ and NO~3~^-^ was determined as an index of total NO production. The total NO concentration in the samples was done according to Griess method \[[@pone.0231472.ref035]\]. Lastly, total antioxidant capacity (T-AOC) was quantified by a method reported by Miller et al \[[@pone.0231472.ref036]\] where a reaction between 2,2'-azinobis-(3- ethyl-benzothiazoline-6-sulphonic acid) and peroxidase results in a relatively stable radical cation which upon interaction with Ferryl Myoglobin produces a relatively stable product that can be measured spectrophotometrically. The principle is based on the inhibition of 2, 2'-Azino-di-\[3-ethylbenzthiazdine sulphonate\] radical (ABTS^R^) by antioxidants in the plasma. Radical cation ABTS^R+^ was generated by incubation of ABTS^R^ with a peroxidase (metmyoglobin) and H~2~O~2~. All assays were carried out according to the manufacturer guidlines (NJJC Bio, Nanjing JianCheng, Bioengineering Institute, China).

Histopathological studies {#sec010}
-------------------------

The left kidney was carefully isolated from adipose and connective tissues. The excised kidney was then blotted dry on a laboratory filter paper and preserved in 10% neutral buffered formalin solution until histological examination. All tissues underwent a procedure reported using Haematoxylin and Eosin (H&E) staining \[[@pone.0231472.ref009], [@pone.0231472.ref027]\]. Histology was examined by a pathologist in this university (Dr G. K.). Kidney index (KI) was calculated using a standard equation (Kidney index = kidney weight / body weight x 100).

Relative quantification of NOX4 mRNA expression in the kidney using StepOnePlus RT-PCR system {#sec011}
---------------------------------------------------------------------------------------------

The contralateral kidney was harvested and stored in RNAlater solution (Ambion, Life Technologies, Pleasanton, CA, USA) at -80°C in order to sustain the RNA integrity until further procedure. The quantitative RT-PCR reaction was performed on all eight experimental groups with a total of 64 rat kidney samples. Each rat kidney sample was further analysed in a triplicate manner. The extraction procedure was performed under a sterile environment. All equipment (harvesting desk, beaker, tissue, test tubes, surgical blades, and scissors) was cleaned with RNAZap^®^ solution (Ambion, Life Technologies Corporation, USA) to prevent any possible contamination. TRIzol reagent (Ambion, Life Technologies Corporation, USA) was used to extract RNA from kidney tissue according to the manufacturer's guidelines. Upon various sequential steps of homogenization, washing and elution, total RNA was extracted, optimized, and quantified for purity using a NanoDrop^™^ Lite UV-Vis Spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) followed by total RNA to cDNA conversion using a high capacity RNA-to-cDNA kit (Applied Biosystems, Waltham, MA, USA). A volume of 20 μl of RNA was used for the conversion of cDNA using the default setting of the StepOnePlus RT-PCR system (Applied Biosystems, Singapore). Of the 20 μl, 11 μl comprised kit components (2× buffer, 10 μl; 20× enzymes, 1 μl), and the remaining 9 μl consisted of total RNA (depending upon the yield). TaqMan primers and probes for Nox4 gene (GenBank Accession N0. AY027527.1 and Rn00585380_m1) were derived from TaqMan-Gene Expression assays (Applied Biosystems, Waltham, MA, USA) \[[@pone.0231472.ref037]\]. Similarly, TaqMan primers and probes for β-actin gene (endogenous control, GenBank Accession N0. NM 031144.3 and Rn00667869_m1) were also derived from TaqMan-Gene Expression assays (Applied Biosystems, Waltham, MA, USA).

TaqMan Gene Expression assays were performed according to the manufacturer's protocol. The amplification began with a total 20 μl reaction mixture. One RT-PCR reaction consisted of 10 μl of TaqMan Fast Master Mix (2×); 1 μl of TaqMan Gene Expression assays (20×) of the respective genes Nox 4 and β-actin; 8 μl of RNase-free water (Invitrogen, Carlsbad, CA, USA); and 1 μl of unknown sample cDNA. Temperature settings were done according to the manufacturer's default settings. The amplification reactions were carried out on a MicroAmp^®^ Fast 96-well reaction plate (0.1 ml, Applied Biosystems, Life Technologies).

Quantitative RT-PCR reactions were performed on renal cortex of the extracted kidneys. Amplification of the housekeeping enzyme β-actin (endogenous control) allowed sample loading and normalization to be determined. The relative quantification of the target gene Nox4 and β-actin was calculated using the comparative C~T~ (threshold cycle) method with arithmetic formula (2^-ΔΔCT^) \[[@pone.0231472.ref038]\].

The statistical analysis for the study was done using GraphPad Prism Version 5 software (GraphPad Software, San Diego, California, USA). All data retrieved from metabolic, renal functional, oxidative stress markers, haemodynamics and molecular studies were analysed with repeated measure one-way ANOVA followed by Bonferroni *post hoc* test. All data were presented as mean ± S.E.M with significance at P\<0.05 level.

Results {#sec012}
=======

Apocynin and catalase ameliorated reduction in body weight and water intake in CsA rats {#sec013}
---------------------------------------------------------------------------------------

The daily intake of food and water was similar across all experimental groups but there was a reduction (P\<0.05) in body weight gain in the CsA group. Treatment of CsA rats with apocynin and catalase enhanced body weight gain compared to untreated rats by the end of the treatment period ([Fig 1](#pone.0231472.g001){ref-type="fig"}). There was a decrease in water intake (P\<0.05) in CsA rats compared to control rats at day 7 and 14 of the study period. However, treatment of CsA rats with apocynin and apocynin plus catalase but not catalase alone resulted in greater water intake compared to untreated rats ([Fig 2](#pone.0231472.g002){ref-type="fig"}).

![Body weight values during the study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \* p\<0.05 from Day 0; \# p\<0.05 of Cx vs. C (Day 14); ¥ p\<0.05 of all groups vs. C except Cx (Day 14); † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx (Day 14); § p\<0.05 of CxApo vs. CxApoCat (Day 14); ¶ p\<0.05 of CxCat vs. CxApoCat (Day 14); δ p\<0.05 of CxCat vs. CxApo (Day 14).](pone.0231472.g001){#pone.0231472.g001}

![Water intake during the study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \* p\<0.05 from Day 0; \# p\<0.05 of Cx vs. C (Day 14); ¥ p\<0.05 of all groups vs. C except Cx (Day 14); † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx (Day 14).](pone.0231472.g002){#pone.0231472.g002}

Apocynin and catalase restored renal excretory function in CsA rats {#sec014}
-------------------------------------------------------------------

Urine volume did not change during the study period in all groups except for CsA rats where a significant reduction (P\<0.05) in urine excretion compared to baseline was observed on day 7 and remained low on day 14 of the study. Treatment of CsA rats with apocynin, catalase, and a combination of apocynin and catalase restored urine output to near control values ([Fig 3](#pone.0231472.g003){ref-type="fig"}).

![Urine output during the study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \* p\<0.05 from Day 0; \# p\<0.05 of Cx vs. C (Day 14); † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx (Day 14).](pone.0231472.g003){#pone.0231472.g003}

CsA resulted in a decreased (P\<0.05) creatinine clearance from baseline value (day 0) on day 7 and 14 of the study. The creatinine clearance in CsA group on day 14 of the study was smaller (P\<0.05) compared to respective value in control group. The treatment of CsA rats with apocynin and a combination of apocynin and catalase increased creatinine clearance to values comparable to control at the end of treatment period as shown in [Fig 4](#pone.0231472.g004){ref-type="fig"}.

![Creatinine clearance during the study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \* p\<0.05 from Day 0; \# p\<0.05 of Cx vs. C (Day 14); ¥ p\<0.05 of all groups vs. C except Cx (Day 14); † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx (Day 14); § p\<0.05 of CxApo vs. CxApoCat (Day 14); ¶ p\<0.05 of CxCat vs. CxApoCat (Day 14); δ p\<0.05 of CxCat vs. CxApo (Day 14).](pone.0231472.g004){#pone.0231472.g004}

The fractional excretion of sodium ([Fig 5](#pone.0231472.g005){ref-type="fig"}) and urinary sodium to potassium ratio ([Fig 6](#pone.0231472.g006){ref-type="fig"}) were not changed in control rats, those treated with apocynin, catalase, and their combination. However, in CsA treated rats, there was a significant reduction (P\<0.05) in these parameters at day 7 and 14 of the study. Administration of apocynin, catalase, and a combination of apocynin and catalase improved (P\<0.05) the fractional excretion of sodium and urinary sodium to potassium ratio in CsA especially by day 14. A similar pattern of results was seen for urinary protein excretion in CsA rats treated with apocynin, catalase, and their combination in that there was a decrease (all P\<0.05) in urinary protein levels to baseline values (day 0) as early as 7 days after initiation of the treatment. Moreover, individual or combined treatment of CsA rats with apocynin and catalase resulted in near control urine protein values in these rats as demonstrated in [Fig 7](#pone.0231472.g007){ref-type="fig"}.

![Fractional excretion of sodium during the study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \* p\<0.05 from Day 0; \# p\<0.05 of Cx vs. C (Day 14); ¥ p\<0.05 of all groups vs. C except Cx (Day 14); † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx (Day 14).](pone.0231472.g005){#pone.0231472.g005}

![Urinary Na^+^:K^+^ ratio during the study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \* p\<0.05 from Day 0; \# p\<0.05 of Cx vs. C (Day 14); † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx (Day 14).](pone.0231472.g006){#pone.0231472.g006}

![Urinary protein excretion during the study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \* p\<0.05 from Day 0; \# p\<0.05 of Cx vs. C (Day 14); † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx (Day 14).](pone.0231472.g007){#pone.0231472.g007}

There was a significant increase (P\<0.05) in kidney index in CsA rats as compared to control rats as shown in [Fig 8](#pone.0231472.g008){ref-type="fig"}. However, treatment of CsA rats for 14 days with apocynin, catalase, and their combination decreased (P\<0.05) kidney index compared to untreated CsA rats. No changes in kidney index were observed in control rats treated with apocynin, catalase, and a combination of apocynin and catalase.

![Kidney index at the end of 14 days study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx.](pone.0231472.g008){#pone.0231472.g008}

The BUN values for treatment groups at day 16 of the study are shown in [Fig 9](#pone.0231472.g009){ref-type="fig"}. The BUN in CsA group was significantly higher (P\<0.05) as compared to control group. However, CsA rats treated with apocynin, catalase, and especially their combination showed significantly lower BUN compared to untreated CsA. BUN levels in control rats treated with apocynin, catalase or their combination were not different from their untreated counterparts.

![Blood urea nitrogen at the end of 14 days study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. ¥ p\<0.05 of all group vs. C except Cx; \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx; § p\<0.05 of CxApo vs. CxApoCat; ¶ p\<0.05 of CxCat vs. CxApoCat.](pone.0231472.g009){#pone.0231472.g009}

Apocynin and catalase treatment restored blood pressure and heart rate in CsA rats {#sec015}
----------------------------------------------------------------------------------

Baseline SBP and heart rate were similar in the eight experimental groups. SBP was significantly (P\<0.05) higher than baseline levels in CsA rats at day 7 and day 14 of the treatment period. Similarly, heart rate was also increased significantly (P\<0.05) from baseline in CsA and CsA rats treated with catalase starting at day 7 and continued until the end of the 14-day study period. Treatment of CsA rats with apocynin, catalase or a combination of apocynin and catalase significantly attenuated the increase in both SBP and heart rate as shown in Figs [10](#pone.0231472.g010){ref-type="fig"} and [11](#pone.0231472.g011){ref-type="fig"}.

![Systolic blood pressure values during the study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \* p\<0.05 from Day 0; \# p\<0.05 of Cx vs. C (Day 14); ¥ p\<0.05 of all groups vs. C except Cx (Day 14); † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx (Day 14).](pone.0231472.g010){#pone.0231472.g010}

![Heart rate values during the study period in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \* p\<0.05 from Day 0; \# p\<0.05 of Cx vs. C (Day 14); ¥ p\<0.05 of all groups vs. C except Cx (Day 14); † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx (Day 14).](pone.0231472.g011){#pone.0231472.g011}

Apocynin and catalase restored renal and systemic hemodynamic parameters in CsA rats {#sec016}
------------------------------------------------------------------------------------

The basal values of RCBP in CsA rats were significantly lower (P\<0.05) as compared to control rats. However, treatment of CsA rats with apocynin, catalase, and especially their combination inhibited this decrease in RCBP compared to untreated CsA rats. No differences were observed in RCBP between control rats treated with apocynin, catalase or a combination of apocynin and catalase ([Fig 12](#pone.0231472.g012){ref-type="fig"}).

![Renal cortical blood perfusion measured during acute experiment on Day 14 in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx; ¶ p\<0.05 of CxCat vs. CxApoCat.](pone.0231472.g012){#pone.0231472.g012}

PWV is used clinically as a parameter of aortic stiffness and an established marker of cardiovascular risk. In this study, CsA rats had a higher (P\<0.05) PWV at the end of the study period compared to their control counterparts. However, treatment of CsA rats with apocynin, catalase or a combination of apocynin and catalase restored the PWV values to near normal values. No significant differences were observed in PWV values in untreated control rats or those treated with either apocynin, catalase or a combination of apocynin and catalase ([Fig 13](#pone.0231472.g013){ref-type="fig"}).

![Pulse wave velocity measured during acute experiment on Day 14 in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx.](pone.0231472.g013){#pone.0231472.g013}

β-index is used to quantify the intrinsic exponent of the blood pressure and vascular diameter relationship. Unlike the other treatment groups, CsA treated rats had a significantly higher (P\<0.05) β-index. Administration of apocynin, catalase or a combination of apocynin and catalase restored the β-index in CsA treated rats to values comparable to control ([Fig 14](#pone.0231472.g014){ref-type="fig"}).

![β-Index measured during acute experiment on Day 14 in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Data presented as mean±SEM. \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx.](pone.0231472.g014){#pone.0231472.g014}

Apocynin and catalase inhibited the increase in oxidative stress markers due to CsA {#sec017}
-----------------------------------------------------------------------------------

The plasma and kidney levels of malondialdehyde (MDA) are depicted in Figs [15](#pone.0231472.g015){ref-type="fig"} and [16](#pone.0231472.g016){ref-type="fig"}, respectively. CsA rats have higher (P\<0.05) plasma MDA levels compared to control rats. However, treatment of CsA rats with apocynin, catalase or a combination of apocynin and catalase restored MDA levels to near normal levels. However, plasma MDA in catalase treated CsA rats was higher (P\<0.05) compared to CsA rats treated with a combination of apocynin and catalase. No significant changes in plasma MDA levels were observed in untreated or apocynin, catalase or apocynin plus catalase treated control rats ([Fig 15](#pone.0231472.g015){ref-type="fig"}). The kidney level of MDA in CsA rats was higher (P\<0.05) than control rats. However, treatment of CsA rats with apocynin, catalase or a combination of apocynin and catalase resulted in decreased (P\<0.05) kidney MDA levels compared to untreated CsA rats ([Fig 16](#pone.0231472.g016){ref-type="fig"}).

![Plasma level of malondialdehyde (MDA) in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Values are mean±SEM. ¥ p\<0.05 of all group vs. C except Cx; \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx; § p\<0.05 of CxApo vs. CxApoCat; ¶ p\<0.05 of CxCat vs. CxApoCat; δ p\<0.05 of CxCat vs. CxApo.](pone.0231472.g015){#pone.0231472.g015}

![Kidney level of malondialdehyde (MDA) in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Values are mean±SEM. ¥ p\<0.05 of all group vs. C except Cx; \# p\<0.05 of Cx versus C; and † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx.](pone.0231472.g016){#pone.0231472.g016}

The activity of SOD in the plasma and kidney of experimental groups are shown in Figs [17](#pone.0231472.g017){ref-type="fig"} and [18](#pone.0231472.g018){ref-type="fig"}, respectively. CsA rats had a significantly lower (P\<0.05) plasma SOD activity as compared to control. The administration of apocynin in combination with catalase, or either drug alone, in the CsA rat resulted in higher (P\<0.05) SOD activity compared to untreated rats. In addition, there was a significantly higher plasma SOD activity level in control rats treated with apocynin or apocynin plus catalase compared to untreated controls ([Fig 17](#pone.0231472.g017){ref-type="fig"}). SOD activity in the kidney was lower (P\<0.05) in CsA rats compared to control but was similar to control levels in CsA rats treated with apocynin, catalase or a combination of apocynin and catalase ([Fig 18](#pone.0231472.g018){ref-type="fig"}).

![Plasma level of total superoxide dismutase activity (T-SOD) activity in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Values are mean±SEM. ¥ p\<0.05 of all group vs. C except Cx; \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx; § p\<0.05 of CxApo vs. CxApoCat; ¶ p\<0.05 of CxCat vs. CxApoCat; δ p\<0.05 of CxCat vs. CxApo.](pone.0231472.g017){#pone.0231472.g017}

![Kidney level of superoxide dismutase activity (SOD) in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Values are mean±SEM. ¥ p\<0.05 of all group vs. C except Cx; \# p\<0.05 of Cx vs. C; and † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx.](pone.0231472.g018){#pone.0231472.g018}

Plasma nitric oxide (NO) activity in the different treatment groups is illustrated in [Fig 19](#pone.0231472.g019){ref-type="fig"}. The plasma NO activity in CsA rats was lower (P\<0.05) compared to control rats. Treatment of CsA rats with apocynin, catalase, and their combination restored NO activity back towards normal levels. The plasma NO activity in control rats treated with apocynin and apocynin plus catalase was significantly higher (P\<0.05) than untreated control rats.

![Plasma level of nitric oxide (NO) activity in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Values are mean±SEM. ¥ p\<0.05 of all group vs. C except Cx; \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx; δ p\<0.05 of CxCat vs. CxApo.](pone.0231472.g019){#pone.0231472.g019}

The plasma levels of T-AOC in CsA rats were lower (P\<0.05) than their control counterparts. However, the levels of T-AOC in CsA rats treated with apocynin, catalase, and the combination of apocynin and catalase were higher compared to the rats without therapy ([Fig 20](#pone.0231472.g020){ref-type="fig"}). On another hand, the plasma levels of T-AOC in control rats treated with apocynin and apocynin plus catalase were higher than untreated controls. The kidney levels of T-AOC in CsA rats were also lower (P\<0.05) compared to their control counterparts. Administration of apocynin, catalase, and a combination of apocynin and catalase resulted in higher kidney tissue T-AOC (P\<0.05) compared to untreated CsA rats [Fig 21](#pone.0231472.g021){ref-type="fig"}.

![Plasma level of total antioxidant capacity (T-AOC) in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Values are mean±SEM. ¥ p\<0.05 of all group vs. C except Cx; \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx.](pone.0231472.g020){#pone.0231472.g020}

![Kidney level of total antioxidant capacity (T-AOC) in control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Values are mean±SEM. \# p\<0.05 of Cx vs. C; and † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx.](pone.0231472.g021){#pone.0231472.g021}

Apocynin and catalase restored renal Nox4 mRNA expression in CsA rats {#sec018}
---------------------------------------------------------------------

Nox4 mRNA expression in CsA group was higher, by some 64% (P\<0.05), compared to control group. However, treatment of CsA rats with apocynin alone resulted in similar Nox4 expression to control rats treated with apocynin. Likewise, the level of Nox4 mRNA expression in CsA rats treated with catalase alone was comparable to untreated controls. The treatment of CsA rats with a combination of catalase and apocynin resulted in lower Nox4 mRNA expression when compared to untreated CsA rats (all P\<0.05) as shown in [Fig 22](#pone.0231472.g022){ref-type="fig"}. The level of kidney Nox4 mRNA expression was lower by almost 35% (P\<0.05) in apocynin treated compared to untreated control rats. A similar observation was seen in control rats treated with a combination of apocynin and catalase where Nox4 expression was lower than untreated rats.

![The molecular expression of Nox 4 mRNAs in the renal cortex of control (C), Apocynin (Apo), Catalase (Cat), Apocynin plus Catalase (ApoCat), CsA (Cx), CsA plus Apocynin (CxApo), CsA plus Catalase (CxCat), and CsA plus a combination of Apocynin and Catalase (CxApoCat) treated rats.\
CsA, Cyclosporine A. Values are mean±SEM. ¥ p\<0.05 of all group vs. C except Cx; \# p\<0.05 of Cx vs. C; † p\<0.05 of CxApo, CxCat and CxApoCat vs. Cx; § p\<0.05 of CxApo vs. CxApoCat; ¶ p\<0.05 of CxCat vs. CxApoCat; δ p\<0.05 of CxCat vs. CxApo.](pone.0231472.g022){#pone.0231472.g022}

Apocynin and catalase prevented structural alterations due to CsA-induced tissue damage {#sec019}
---------------------------------------------------------------------------------------

The kidney tissues did not show any ultra-structural alterations in the glomerulus and tubules components in control rats treated or not with apocynin, catalase, and a combination of apocynin and catalase as demonstrated in [Fig 23A, 23B, 23C and 23D](#pone.0231472.g023){ref-type="fig"}. The kidney tissues of CsA rats showed severe renal tubular ischaemia ([Fig 23E2](#pone.0231472.g023){ref-type="fig"}, solid arrow) as well as abscesses in the renal interstitium area. Neutrophils surrounded by foamy macrophages were also observed beyond the subcapsular region ([Fig 23E1, 23E2 & 23E3](#pone.0231472.g023){ref-type="fig"}, open arrow). A deformed glomerular apparatus characterized by thickening of Bowmen's capsules was also observed in CsA rats ([Fig 23E1](#pone.0231472.g023){ref-type="fig"}, solid arrow). There was also a possible striped interstitial fibrosis ([Fig 23E3](#pone.0231472.g023){ref-type="fig"}, solid arrow). All structural changes in the kidney of CsA rats were not detected following apocynin, catalase or combined apocynin and catalase treatment ([Fig 23F, 23G & 23H](#pone.0231472.g023){ref-type="fig"} respectively).

![Histopathological study of renal tissue of control (C) \[A\], Apocynin (Apo) \[B\], Catalase (Cat) \[C\], Apocynin plus Catalase (ApoCat) \[D\], CsA (Cx) \[E1, E2 & E3\], CsA plus Apocynin (CxApo) \[F\], CsA plus Catalase (CxCat) \[G\], and CsA plus a combination of Apocynin and Catalase (CxApoCat) \[H\] treated rats.\
Arrows indicate the area of the renal tissue with histological changes. CsA, Cyclosporine A. (Haematoxylin and eosin stain; original magnification x100).](pone.0231472.g023){#pone.0231472.g023}

Discussion {#sec020}
==========

The present study examined the combined effect of NADPH oxidase inhibition using apocynin and H~2~O~2~ scavenging using catalase on CsA-induced renal injury. CsA rats in the present study demonstrated hypertension, impaired renal function and elevated oxidative stress. Moreover, histopathological examination of CsA rat kidney showed inflammatory cells infiltration and interstitial fibrosis. Therefore, CsA induces an oxidative stress cascade with negative impacts on both renal excretory function and renal histology leading to hypertension. The novel finding of this study is that treatment of CsA renal injury rats with a combination of apocynin and catalase for 14 days ameliorated hypertension, renal dysfunction and oxidative stress.

The administration of CsA for 14 days in this study impaired renal function as manifested by a decrease in creatinine clearance and urinary sodium excretion as well as kidney tissue damage as shown by histology. There was a significant decrease in body weight of CsA treated rats which began on day 7 of the study and onward. Morphake et al., \[[@pone.0231472.ref039]\] showed using CsA model in rats a decrease in creatinine clearance in addition to body weight loss by almost 13% within 7 days of CsA treatment. This magnitude is comparable to the loss in body weight in the present study after 7 days. The reason of this loss is possibly related to anorexic effect of CsA and in agreement with previous studies in rats \[[@pone.0231472.ref039]--[@pone.0231472.ref041]\]. Weight loss can also be attributed to the higher metabolic rate in response to the catabolic action of CsA \[[@pone.0231472.ref042]\]. In addition to body weight loss, CsA treatment was associated with a significant increase in blood pressure as early as 7 days of the study. Likewise, there was an increase in heart rate which is possibly related to augmented sympathetic nerve activity in this model \[[@pone.0231472.ref043]\]. In relation to that, an activation of renal afferent nerve activity was reported before that led to a reflex sympathoexcitation and increased blood pressure and heart rate \[[@pone.0231472.ref044], [@pone.0231472.ref045]\]. The treatment of CsA rats with a combination of apocynin and catalase in this study ameliorated the body weight loss and restored blood pressure and heart rate values towards normal. Indeed, treatment with either apocynin or catalase was shown to have an antihypertensive effect in this study as well as previous studies \[[@pone.0231472.ref046], [@pone.0231472.ref047]\].

The present study showed a reduction by more than 50% in the fractional excretion of sodium (FE~Na+~) from its baseline value (day 0) after 14 days of CsA treatment. This effect of CsA on sodium reabsorption has been suggested to contribute to the increase in blood pressure in this model \[[@pone.0231472.ref048]\]. The decrease in sodium excretion in CsA rats in this study is related to increased expression of epithelial sodium channels (ENaC) in the nephron which was previously reported in CsA treated allogeneic rat model \[[@pone.0231472.ref049]\]. Moreover, in spontaneously hypertensive rat (SHR) which is a model of renal injury and hypertension there is enhanced expression of ENaC with possible role in sodium retention observed during the course of hypertension in this model \[[@pone.0231472.ref050]\]. Impaired sodium excretion in CsA model can also be due to O~2~^−^induced activation of protein kinase C \[[@pone.0231472.ref051]\] and increased activity of apical membrane Na^+^-K^+^-2Cl^-^ co-transporter in the thick ascending limb of the loop of Henle \[[@pone.0231472.ref052]\]. Based on these studies, the mechanism of decreased sodium excretion in CsA model can be multifaceted.

The CsA rats in this study also showed a decrease in urinary sodium to potassium ratio after 7 days of CsA treatment initiation. This finding points to a possible involvement of renin-angiotensin aldosterone system in CsA-induced hypertension in this model. This notion is supported by a recent study using CsA in rats which showed that aldosterone is a key mediator of renal injury in this model an effect which can be inhibited by aldosterone antagonists \[[@pone.0231472.ref034]\]. Indeed, apocynin treatment of CsA rats in this study restored the sodium to potassium ratio. A previous study showed that apocynin inhibits aldosterone/salt-induced kidney damage by preventing the production of prostaglandin E~2~ (PGE~2~) in Dahl salt-sensitive rat model \[[@pone.0231472.ref053]\]. Furthermore, an inverse relationship was reported between baseline 24-h urinary sodium to potassium ratio and the 24-h urinary potassium excretion especially during diuresis in SHR model which is characterised by sympathetic hyperactivity \[[@pone.0231472.ref025], [@pone.0231472.ref054]\]. The effects of apocynin and catalase in the present study on urinary sodium to potassium ratio could possibly be linked to their inhibitory effect on ROS and consequently on sympathetic hyperactivity \[[@pone.0231472.ref055]\]. CsA treatment in this study was associated with increased urinary protein excretion and structural alterations such as deformation of glomerular apparatus, tubular ischemia and the presence of inflammatory exudates in the subcapsular region. The combined administration of apocynin and catalase in this study exerted a protective effect against CsA-induced kidney injury due to O~2~^-^ and H~2~O~2~ removal from tissues by these compounds respectively \[[@pone.0231472.ref056], [@pone.0231472.ref057]\].

The CsA-induced renal injury in this study was accompanied by a decrease in renal cortical blood perfusion. A previous study by Prevot et al, \[[@pone.0231472.ref058]\] showed a relationship between decreased renal blood flow in this model and local vasoconstrictive mechanism in the kidney. Several mechanisms could be involved such as activation of the renin-angiotensin system, imbalances in prostaglandins, thromboxane and hypersecretion of endothelin-1 can also play a role in CsA-induced renal vasoconstriction \[[@pone.0231472.ref001]\]. Treatment of CsA rats with apocynin and catalase in the present study increased renal cortical blood perfusion compared to CsA rats without treatment. The combined treatment with apocynin and catalase had a greater effect on renal blood perfusion compared to individual treatment. This observation suggests that concomitant NADPH oxidase inhibition and H~2~O~2~ hydrolysis might be required to maximise the antioxidant effect. This can be looked at in the context of the classical oxidative pathway where O~2~^-^ is converted into H~2~O~2~ by SOD enzyme which will be eventually converted into H~2~O and molecular O~2~. However, a heightened O~2~^-^ dismutation alone in the absence of concomitant increase in catalase activity would result in oxidative stress mediated by H~2~O~2~ abundance. Therefore, direct NADPH oxidase inhibition in addition to continuous hydrolysis of H~2~O~2~ using apocynin and catalase combined treatment can provide a better oxidative defence against CsA-induced renal injury.

The plasma and kidney MDA levels in this study were significantly higher in CsA rats compared to controls. In relation to that, it was suggested that CsA impairs mitochondrial electron transport and cytochrome P450-3A activity leading to oxidative stress \[[@pone.0231472.ref059]\]. Regardless of the source of free radicals, intervention that blocks this pathway may be an effective strategy to prevent ROS-mediated kidney damage. The combined treatment of CsA rats with apocynin and catalase in this study restored MDA levels to near normal values both locally and in the plasma.

The pulse wave velocity parameters were significantly impaired in CsA rats in the present study. Indeed, oxidative stress is well studied as a cause of altered arterial elasticity \[[@pone.0231472.ref060]\]. This finding is consonant with a report on the acute effect of CsA on haemodynamics in the large arteries in kidney transplant patients \[[@pone.0231472.ref061]\]. Treatment of CsA rats with a combination of apocynin and catalase restored pulse wave velocity and improved the β-index possibly due to up-regulation of antioxidant enzymes that drive the scavenging activity of NADPH oxidase. This reduces ROS production and speeds up the conversion of H~2~O~2~ to O~2~ and H~2~O \[[@pone.0231472.ref062]\] with effects on haemodynamics.

NOX4 is readily distinguished from other NADPH oxidase isoforms in the NOX family of proteins by its high level of expression in renal tissues \[[@pone.0231472.ref063]\]. It was evident that, within the renal cortex, NADPH oxidase activity was significantly elevated in rats subjected to CsA \[[@pone.0231472.ref046]\]. The findings of the present study demonstrated that CsA administration increases NOX4 expression in the renal homogenates and it is thought to be consistent with its involvement in the generation of O~2~^-^. In line with these findings, previous investigations showed elevated expression of NOX4 in a number of cardiovascular diseases including atherosclerosis, hypertension, cardiac failure and ischemic stroke \[[@pone.0231472.ref064]\]. Treatment of CsA rats with a combination of apocynin and catalase in this study decreased NOX4 mRNA expression to a greater extent compared to individual treatment with either apocynin or catalase alone. This could be related to the crosstalk between direct O~2~^-^ elimination by apocynin and continuous H~2~O~2~ hydrolysis by catalase. It has also been suggested that apocynin and catalase prevent translocation of the cytosolic components of NOX, p47^phox^ to gp91^phox^ required to form the active oxidase \[[@pone.0231472.ref065]\]. Both apocynin and catalase exerted the same degree of protection against Dahl salt sensitive rat hypertension model in a previous study \[[@pone.0231472.ref066]\]. The findings of this study further demonstrate a stronger effect due to combined treatment with apocynin and catalase in ameliorating oxidative stress in CsA model of renal injury.

Conclusion {#sec021}
==========

Our findings suggest that renal injury in CsA model was associated with an increase in NADPH oxidase activity, which contributes to the production of O~2~^-^ and to the development of renal injury and hypertension. The prophylactic treatment with apocynin and catalase for 14 days maintained normal blood pressure and improved renal function which eventually halted CsA-induced tissue damage. Based on renal functional and oxidative stress data, the current study demonstrated that apocynin provides more defence against oxidative stress, impaired kidney function and hypertension compared with catalase. Combined treatment with apocynin and catalase had a greater effect compared to individual drug in restoring blood pressure and renal function. Taken together, inhibiting NADPH oxidase by apocynin, catalase, and their combination prevents the onset of hypertension and renal injury induced by CsA.
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2\) Introduction: The authors say that CsA is a widely used immunosuppressant in organ transplantation. What is the rate of occurrence of nephrotoxicity in these patients clinically?

3)Introduction: Mention that IL-2 is an anti-inflammatory cytokine.

4\) Introduction: Give a bit more detail about how CsA prevents activation of T cells via cyclophilins.

5\) Introduction: The authors mention that CsA induced nephrotoxicity has been documented in both humans and animals, and then go on to describe a few of these studies. Please distinguish which studies were performed in humans, and which in animals. Is this an exhaustive reporting on known literature?

6\) Introduction: It is known that NADPH oxidase (Nox) has a function in normal physiology. Elaborate why excessive levels of Nox are bad. Has this been documented in humans? What is the etiology of excessive Nox and the related pathophysiology in a diseased state?

7\) Introduction: Please elaborate more on the mechanism of action of apocynin.

8\) Materials and methods: What is \'plethysmography\'?

9\) Materials and methods: The timeline of the animal study is a bit confusing. At what point was the study stopped, and the animals euthanized? Is it 14 days?

10\) Materials and methods: Whats is Pulse wave velocity? Explain it\'s significance.

11\) Materials and methods- Biochemical analysis of oxidative stress markers: Elaborate a bit more on the principle and technique of some of the assays used to measure these markers. T-AOC methods takes into account which specific antioxidants?

12\) Materials and methods- Histopathological studies: Mention what kind of stain was used.

13\) Results: All the titles in the results section should reflect actual experimental findings instead of generic titles such as \'Effect of\...\'. For example, use \'Apocynin and catalase treatment ameliorated reduction and body weight and water intake seen with CsA treated rats.\'

14\) Figures: It is highly recommended that the data presented in Table 1 and Table 2 be presented as graphs with histograms. Visual data has more of an impact than obscure numbers in a table. Table 1 can be a multi-paneled figure 1 and Table 2 can likewise be figure 2. The paper would thus have 5 figures instead of 3.

15\) Figure 3: Make it Figure 5, and please include a colored image instead.

16\) Figure 3: It would be good if the authors could perform staining of histopathological sections for Nox 4 and some other markers such as MDA, SOD etc. Again, visual data is more impactful.

14\) Discussion: Line 354: \....treatment of CsA injury rats with apocynin and catalase for 14 days ameliorated renal function\....; Please use \'dysfunction\' instead of \'function\'.

15\) Discussion- Line 355: Check sentence construction-Please correct sentence and say that CsA induces\.... a \'negative\'impact on both renal function and structure.

16\) Discussion: What is FeNa+?

17\) Discussion: Please elaborate findings in all the studies that have been referenced. Some studies have been described, some not. These include findings from references 23, 24, 33, 34, 35, 44. Actually, give more details for all studies referenced in the discussion section. What experimental model were they conducted in?

18\) Discussion: It seems that in ref 34 and 35, the effect of apocynin and catalase together has already been demonstrated. Is this true, or was it by single drug only?

19\) Discussion: The authors have discussed their findings and compared them with studies done previously where either apocynin or catalase was used. It is confusing if there is a study where both have been combined previously? If not, then this is the novel aspect of their study, and the authors need to emphasize on this and highlight this properly in their discussion, as this is not immediately obvious.

20\) Discussion: In the studies describing the effects of apocynin or catalase, which were done in humans? Were there any side effects observed?

21\) Did the rats demonstrate any side effects besides the documented effects?

22\) Conclusion: The statement in Line 448 where the authors say that their findings suggest that renal injury in CsA model was associated with hypertension\.....This is not a novel finding, as the authors describe this in the introduction (Ref 4). They present it as a novel finding though.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

13 Dec 2019

Answers to reviewer's comment

Paper No. PONE-D-19-26893

Title: "Apocynin and catalase prevent hypertension and kidney injury in Cyclosporine A induced nephrotoxicity in rats''

PLOSONE

First of all, we would like to thank the Reviewers for their comments on our manuscript. We would also thank the editor for giving his consideration to this manuscript.

Reviewer \#1:

The study evaluated the effect of apocynin and catalase in cyclosporine A-induced nephrotoxicity. Several biomarkers of oxidative stress were determined due to oxidative stress participated in nephrotoxicity as an important pathogenesis mechanism. The authors tested the MDA, SOD, NO and AOC level in plasma from different groups. Why do the authors test these biomarkers in the kidney tissue since the major tissue of injury induced by cyclosporine is the kidney tissue?

Authors' response:

Thank you for the important suggestion of measuring MDA, SOD, NO and AOC levels in the kidney tissue. Measuring the levels of MDA, SOD, NO and AOC in the plasma helped us to study the contribution of biomarkers of oxidative stress in hypertension globally and it can be deduced that similar picture may exist locally within the kidney. In the present study, kidney tissue was used to observe the pathological changes in control and treatment groups and expression of NOX 4 mRNA. However, this concept of measuring the kidney levels of biomarkers of oxidative stress can be included in future studies along with their plasma levels to get more accurate and precise information both globally and locally.

The renal function parameters including serum Cr level, blood urea nitrogen (BUN) level, creatinine clearance, proteinuria directly reflected the kidney function and damage condition. BUN level is an important indicator of kidney function. Did the authors test the BUN level in different groups?

Authors' response:

As suggested by the Reviewer, measurement of blood urea nitrogen (BUN) was included in the manuscript at line numbers 148-151 in materials and method and lines 326-331 of results section of the current version of manuscript.

Apocynin can significantly inhibit the activity of NOXes. The authors evaluated the NOX4 mRNA expression in kidney tissue from different groups. Could the author show the NOX4 protein expression in the kidney tissue using IF or IHC?

Authors' response:

Thank you for the comment. The aim of the current study was to explore the expression of NOX4 mRNA in the kidney which ultimately predicts the expression of NOX4 protein. We agree that studying the NOX4 protein expression in the kidney tissue using IF or IHC would have an added value to the presentation in this manuscript and it is one of the limitations of this study. However, we believe that mRNA expression gives an equally important information about overexpression of this protein as a result of the disease process.

Reviewer\#2

In the study, 'Apocynin and catalase prevent hypertension and kidney injury in Cyclosporine A-induced nephrotoxicity in rats\', the authors have demonstrated a potential therapeutic role for the agents combined, in treating harmful side effects associated with CsA treatment. While the study was designed and conducted well, there were some issues as highlighted below:

1\) Abstract: Please rewrite as it is muddled. Do not abbreviate terms (CsA) without first mentioning the proper name. The abstract launches into the experimental design without any background (can be brief) and rationale. Please incorporate these, and structure properly. Also, in describing experimental results, mention the effects of apocynin and catalase alone, and then emphasize that the combinatorial treatment was more potent.

Authors' response:

Author acknowledge and appreciate the Reviewer's input regarding the abstract. In this version of the manuscript the abstract has been amended accordingly to include the required amendments.

2\) Introduction: The authors say that CsA is a widely used immunosuppressant in organ transplantation. What is the rate of occurrence of nephrotoxicity in these patients clinically?

Authors' response:

As suggested by the Reviewer, the incidence of cyclosporine induced nephrotoxicity has been incorporated in the current manuscript at lines 53-58.

3\) Introduction: Mention that IL-2 is an anti-inflammatory cytokine.

Authors' response:

Thank you. Interleukin-2 has now been mentioned as an inflammatory cytokine in line number 61-67.

4\) Introduction: Give a bit more detail about how CsA prevents activation of T cells via cyclophilins.

Authors' response:

As suggested by the Reviewer, effects of CsA in the activation of T cells via cyclophilins have now been mentioned in more details at lines 61-63.

5\) Introduction: The authors mention that CsA induced nephrotoxicity has been documented in both humans and animals, and then go on to describe a few of these studies. Please distinguish which studies were performed in humans, and which in animals. Is this an exhaustive reporting on known literature?

Authors' response:

Thank you. The present study emphasizes the effect of CsA induced nephrotoxicity in rats. Therefore, all the literature reported is mostly related to experimental animals. However, upon suggestions, we distinguished studies in rats from those in humans.

6\) Introduction: It is known that NADPH oxidase (Nox) has a function in normal physiology. Elaborate why excessive levels of Nox are bad. Has this been documented in humans? What is the etiology of excessive Nox and the related pathophysiology in a diseased state?

Authors' response:

Studies in humans reported the effects of NOX4 on tissues such as coronory and other peripheral arteries contributing to atherosclerosis and endothelial dysfunction in these vessels respectively. However, the pattern of and physiological importance of NOX4 expression in human kidney is not fully elucidated. A clinical study depicted the presence of NOX5 in the renal vasculature (J Biol Chem. 2004, 279(18):18583-91) while another study showed correlation between NOX5 expression in the kidney and tissue injury in diabetic nephropathy (Diabetes. 2017, 66(10):2691-2703). The etiology of excessive NOX4 has been investigated before and it was found that it is related at least in part to transforming growth factor-beta (TGF-β) activity in a variety of cell types including endothelial cells and kidney cells (Circ Res. 2005, 97(9):900-7; Front Physiol. 2012; 3: 412). Similarly, it is also reported that tumor necrosis factor-alpha enhances the expression of NOX4 in a variety of vascular cells (Am J Physiol Cell Physiol. 2009, 296(3):C422-32). This has now been included in the introduction part as per the Reviewer's comment.

7\) Introduction: Please elaborate more on the mechanism of action of apocynin.

Authors' response:

As suggested by the Reviewer, the mechanism of action of apocynin is added in the introduction of the current version of the manuscript lines 100-104.

8\) Materials and methods: What is \'plethysmography\'?

Authors' response:

Blood pressure was measured non-invasively using the CODA plethysmograph system. CODA system uses a tail-cuff method to detect blood pressure based on volume changes in the tail. The term plethysmography refers to the method that uses changes in volume to detect changes in pressure. This has now been included under this section of the manuscript lines 154-159.

9\) Materials and methods: The timeline of the animal study is a bit confusing. At what point was the study stopped, and the animals euthanized? Is it 14 days?

Authors' response:

Study was terminated on day 14th and in order to avoid confusion, a clear statement is now included under Animals sub section of the materials and methods.

10\) Materials and methods: What is pulse wave velocity? Explain its significance.

Authors' response:

Pulse wave velocity is a widely used marker of arterial stiffness and was studied in many pathologies such as renal failure, hypertension, left ventricular hypertrophy and diabetes. In humans, pulse wave velocity is utilized as a good predictor of cardiovascular events and mortality. Pulse wave velocity significance is highlighted in the methods section at line number 185-189.

11\) Materials and methods- Biochemical analysis of oxidative stress markers: Elaborate a bit more on the principle and technique of some of the assays used to measure these markers. T-AOC methods takes into account which specific antioxidants?

Authors' response:

As suggested by the Reviewer, principle and detailed technique of all biochemical assays were incorporated at this point under respective sections of the manuscript as in line 217-221 for NO and line 225-227 for T-AOC.

12\) Materials and methods- Histopathological studies: Mention what kind of stain was used.

Authors' response:

Histopathology study was carried out using Hematoxyllin and Eosin staining and is now mentioned in respective part of the manuscript lines 232-235.

13\) Results: All the titles in the results section should reflect actual experimental findings instead of generic titles such as \'Effect of\...\'. For example, use \'Apocynin and catalase treatment ameliorated reduction and body weight and water intake seen with CsA treated rats.\'

Authors' response:

The authors fully agree with the Reviewer's suggestion about the titles of the result sections. In this version of the manuscript we have amended the titles accordingly.

14\) Figures: It is highly recommended that the data presented in Table 1 and Table 2 be presented as graphs with histograms. Visual data has more of an impact than obscure numbers in a table. Table 1 can be a multi-paneled figure 1 and Table 2 can likewise be figure 2. The paper would thus have 5 figures instead of 3.

15\) Figure 3: Make it Figure 5, and please include a colored image instead.

Authors' response:

As suggested by the Reviewer, data in table 1 and 2 are now presented as Figures. Moreover, figure number is now amended accordingly, and colors were made consistent.

16\) Figure 3: It would be good if the authors could perform staining of histopathological sections for Nox 4 and some other markers such as MDA, SOD etc. Again, visual data is more impactful.

Authors' response:

Thank you for the comment. The aim of the current study was to explore the expression of NOX4 mRNA in the kidney which ultimately predicts the expression of NOX4 protein. We agree that histopathological studies of NOX4 and other markers in this study would have an added value to the presentation in this manuscript. However, we believe that mRNA expression gives an equally important information about overexpression of this protein as a result of the disease process. Moreover, the levels of oxidative stress markers in the plasma is still a reliable measure to reflect indirectly on the tissue expression of these markers. On the basis of these findings, this study demonstrated the effect of combined pharmacological intervention using apocynin and catalase on levels of these markers. The suggestion of the Reviewer will be very useful to broaden the scope of our future studies where we can conduct protein expression of the NOX, SOD, MDA mRNAs along with their IHC and IF assays which can be more informative to the readers. This study was conducted in best fashion while addressing these limitations.

14\) Discussion: Line 354: \....treatment of CsA injury rats with apocynin and catalase for 14 days ameliorated renal function\....; Please use \'dysfunction\' instead of \'function\'.

Authors' response:

We apologize for this mistake from our side, it is now corrected.

15\) Discussion- Line 355: Check sentence construction-Please correct sentence and say that CsA induces\.... a \'negative\'impact on both renal function and structure.

Authors' response:

This sentence is now corrected as suggested by Reviewer. Thank you.

16\) Discussion: What is FeNa+?

Authors' response:

We apologize for the typo. In this version of the manuscript we have checked the fractional excretion of sodium abbreviation as FENa+ and amended accordingly as stated in line 144-145.

17\) Discussion: Please elaborate findings in all the studies that have been referenced. Some studies have been described, some not. These include findings from references 23, 24, 33, 34, 35, 44. Actually, give more details for all studies referenced in the discussion section. What experimental model were they conducted in?

Authors' response:

All references highlighted by the Reviewer are explained in the respective sections of the manuscript with the related model and findings. Thank you.

18\) Discussion: It seems that in ref 34 and 35, the effect of apocynin and catalase together has already been demonstrated. Is this true, or was it by single drug only?

Authors' response:

Thank you. Effects of apocynin and catalase were explored in models of kidney injury individually, but they were never been studied in combination in hypertension and kidney injury due to CsA. Moreover, exploration of the NOX4 mRNA in this model after treatment with either apocynin, catalase or a combination of both have never been studied which laid the objective of the present study. A recent study by Ciarcia et al., 2015 (J Cell Biochem. 2015, 116(9):1848-56) showed a protective effect of only apocynin on CsA renal injury without looking at NOX4 mRNA expression and without the use of catalase. Therefore, the present study presents a novel finding that a combined treatment approach is more potent than individual treatment and looked at potential mechanisms for this added effect through NOX4 mRNA expression in the kidney.

19\) Discussion: The authors have discussed their findings and compared them with studies done previously where either apocynin or catalase was used. It is confusing if there is a study where both have been combined previously? If not, then this is the novel aspect of their study, and the authors need to emphasize on this and highlight this properly in their discussion, as this is not immediately obvious.

Authors' response:

As stated above, we are unaware of a study which showed the combined effect of apocynin and catalase on NOX4 expression and on renal function and haemodynamics in CsA model of rats. Discussion is now modified where the novelty of this study was emphasized as per the Reviewer's suggestion.

20\) Discussion: In the studies describing the effects of apocynin or catalase, which were done in humans? Were there any side effects observed?

Authors' response:

Thank you. The authors are unaware of any studies where the role of either apocynin or catalase was examined in humans as these agents are not approved from FDA for human use. However, numerous studies have been conducted on animals to collect scientific information related to both agents. Animals in the present study did not show any sign of toxicity with the dosage level used.

21\) Did the rats demonstrate any side effects besides the documented effects?

Authors' response:

Rats in the present study were monitored daily and did not show any adverse effects. The doses utilized in the present study were also used in previous studies with no reported side effects.

22\) Conclusion: The statement in Line 448 where the authors say that their findings suggest that renal injury in CsA model was associated with hypertension\.....This is not a novel finding, as the authors describe this in the introduction (Ref 4). They present it as a novel finding though.

Authors' response:

The authors fully agree with the Reviewer regarding novelty of hypertension in CsA model. The conclusion of the study is now adjusted to highlight novelty of the present study specifically with regards to combined treatment with apocynin and catalase.
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PONE-D-19-26893R1

Apocynin and catalase prevent hypertension and kidney injury in Cyclosporine A-induced nephrotoxicity in rats

PLOS ONE

Dear Mr TAN SAMUAL,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your manuscript was reviewed by same reviewers and one reviewer raised valid points , which require attention.during revision. Oxidative stress marker(s) in kidney tissue are essential to support the hypothesis of the manuscript.

We would appreciate receiving your revised manuscript by Mar 08 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Partha Mukhopadhyay, Ph.D.

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: NADPH oxidases are a major source of reactive oxygen species (ROS) in the kidney in normal and pathological conditions. Among NADPH oxidase isoforms, NADPH oxidase4 (Nox4) is highly expressed in the kidney and has an important role in kidney diseases.

Nox4 is a NAPDH oxidase expressed in the kidney and has an important role in kidney function injury. In the study, the authors only detected the mRNA expression of Nox4 in kidney tissues from control and treatment groups. mRNA expression didn't completely reflect the protein level and the activity of the protein. How the authors can conclude that the renal injury induced by CsA was associated with the increase in NADPH oxidase activity? In addition, the authors only detect the oxidative stress makers in plasma not the kidney tissue, how to confirm that apocynin and catalase prevent the rental injury through regulating the Nox4 and oxidative stress?

Reviewer \#2: I recommend this manuscript for publication, however, I recommend a couple of minor edits:

1\) Abstract: Add these words in the last sentence: \'NADPH inhibition and H202 scavenging could, therefore, be a potentially important therapeutic strategy to treat CsA-induced nephrotoxicity and hypertension.\'

2\) Abstract: Expand on human studies in references 6-8.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0231472.r004

Author response to Decision Letter 1

7 Mar 2020

Answers to reviewer's comment

Paper No. PONE-D-19-26893

Title: "Apocynin and catalase prevent hypertension and kidney injury in Cyclosporine A induced nephrotoxicity in rats''

PLOSONE

First of all, we would like to thank the Reviewers for their comments on our manuscript. We also thank the Editor for giving his consideration to this manuscript.

Reviewer \#1:

NADPH oxidases are a major source of reactive oxygen species (ROS) in the kidney in normal and pathological conditions. Among NADPH oxidase isoforms, NADPH oxidase4 (Nox4) is highly expressed in the kidney and has an important role in kidney diseases.

Nox4 is a NAPDH oxidase expressed in the kidney and has an important role in kidney function injury. In the study, the authors only detected the mRNA expression of Nox4 in kidney tissues from control and treatment groups. mRNA expression didn't completely reflect the protein level and the activity of the protein. How the authors can conclude that the renal injury induced by CsA was associated with the increase in NADPH oxidase activity? In addition, the authors only detect the oxidative stress makers in plasma not the kidney tissue, how to confirm that apocynin and catalase prevent the renal injury through regulating the Nox4 and oxidative stress?

Authors' response:

The aim of the study was to explore the status of expression of NADPH oxidase in cyclosporine model of kidney injury. The study emphasized that inhibition of this enzyme by administration of apocyanin and catalase will not only downregulate the expression of this enzyme but also will minimize the oxidative stress in the kidney. We showed that NADPH oxidase was indeed downregulated in the kidney by measuring NADPH oxidase mRNA by using qPCR. This downregulation of NADPH oxidase is suggested to translate into decreased protein levels of NADPH oxidase then reduction of oxidative stress biomarkers at the cellular level and in the plasma. As suggested by the Reviewer, we measured the oxidative stress biomarkers in the kidney tissue to relate the expression of NADPH oxidase mRNA with biomarker of oxidative stress. The results showed a similar trend in terms of tissue oxidative stress level as it was shown in the plasma. The levels of oxidative stress biomarkers in different groups are shown in updated Figures 4A, 4B and 4C in the updated version of the manuscript. The present study however presents the limitation that it measured NADPH oxidase mRNA and not the activity of this protein but we believe it highlighted that mRNA expression is altered in this renal injury model and in association with hypertension. Indeed, this study provides the bases for future studies to explore this gap in knowledge.

Reviewer \#2: I recommend this manuscript for publication, however, I recommend a couple of minor edits:

1\) Abstract: Add these words in the last sentence: \'NADPH inhibition and H202 scavenging could, therefore, be a potentially important therapeutic strategy to treat CsA-induced nephrotoxicity and hypertension.\'

Authors' response:

Thank you indeed for the recommending this manuscript for publication. Suggested changes regarding insertion of the above sentence has now been done.

2\) Introduction: Expand on human studies in references 6-8.

Authors' response:

Suggested changes have been done in the introduction section of this manuscript.
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Dear Dr. TAN SAMUAL,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Partha Mukhopadhyay, Ph.D.

Section Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**
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